Last updated: October 28, 2026
Depakote, Abbott’s and later AbbVie’s branded divalproex sodium product, generated more than $1 billion in annual sales before generic erosion. Its core U.S. exclusivity has ended, and the commercial market is now dominated by generic divalproex products. Depakote remains clinically important in epilepsy, bipolar mania, and migraine prevention, but its financial profile has shifted from branded growth to mature, low-margin maintenance demand. No current biosimilar issue applies because Depakote is a small-molecule drug, not a biologic.
What is Depakote and which products are included?
Depakote is the brand name for divalproex sodium, a coordination compound that dissociates into valproate in the gastrointestinal tract. The product family includes multiple dosage forms and release technologies.
| Product |
Active ingredient |
Dosage form |
Primary commercial role |
| Depakote delayed-release tablets |
Divalproex sodium |
Enteric-coated tablet |
Epilepsy, bipolar mania, migraine prevention |
| Depakote ER |
Divalproex sodium |
Extended-release tablet |
Once-daily treatment for epilepsy and bipolar mania |
| Depakote Sprinkle |
Divalproex sodium |
Delayed-release capsules |
Pediatric and swallowing-sensitive patients |
| Generic divalproex sodium |
Divalproex sodium |
Delayed-release, extended-release, sprinkle |
Main source of current U.S. volume |
The FDA-approved indications include complex partial seizures, absence seizures, mixed seizure types, acute manic or mixed episodes associated with bipolar disorder, and migraine prophylaxis. The FDA label does not establish Depakote as an acute migraine treatment.[1]
Valproate products carry boxed warnings for hepatotoxicity, pancreatitis, and fetal risk. The pregnancy-related safety profile has materially affected prescribing, especially among women of childbearing potential.[1]
When did Depakote lose exclusivity?
Depakote lost effective U.S. market exclusivity after generic divalproex products entered the market. Generic competition affected delayed-release tablets first, followed by additional competition for extended-release and other dosage forms.
The important commercial event was not a single patent expiration date but the transition from a branded product with prescription control to a multi-source generic market. Once several manufacturers obtained FDA approval, pharmacy substitution and payer pressure sharply reduced the branded product’s pricing power.
FDA regulatory status
| Regulatory item |
Status |
| Original U.S. approvals |
Granted for multiple Depakote dosage forms over time |
| Current brand status |
FDA-approved product remains listed, but commercial demand is largely generic |
| Small-molecule exclusivity |
Expired |
| Generic approvals |
Available for delayed-release, extended-release, and other divalproex presentations |
| Biosimilar pathway |
Not applicable |
| Orange Book relevance |
Historical patents and product listings remain relevant for approval history; no active brand exclusivity prevents routine generic substitution |
FDA Orange Book listings distinguish the approved Depakote products by NDA, dosage form, and strength. The principal NDAs include Depakote delayed-release tablets, Depakote ER, and Depakote Sprinkle capsules. The Orange Book should be read with FDA’s patent and exclusivity listings because formulation-specific regulatory entries do not create current commercial exclusivity by themselves.[2]
What patents protected Depakote?
Depakote’s historical patent estate covered the active compound, pharmaceutical formulations, release characteristics, and manufacturing or dosage technologies. The commercial value of the estate was concentrated in the original divalproex product and later extended-release formulations.
| Patent category |
Historical commercial function |
Current commercial effect |
| Divalproex compound patents |
Protected the active pharmaceutical product |
Expired |
| Delayed-release formulation patents |
Controlled enteric release and gastrointestinal tolerability |
Expired or no longer blocking ordinary generic entry |
| Extended-release formulation patents |
Supported once-daily dosing and differentiated release profiles |
Historical barrier; generic ER products are now approved |
| Manufacturing patents |
Covered processes or product quality attributes |
Limited practical impact after generic process alternatives became available |
| Method-of-use patents |
Covered epilepsy, bipolar disorder, or migraine-related uses |
Did not preserve broad product exclusivity after generic approval |
Depakote’s patent estate was commercially stronger when the product had few substitutes and physicians associated the brand with specific release profiles. After generic approvals and the expiration of the principal blocking rights, the remaining patent value became defensive rather than revenue-generating.
Were there Paragraph IV challenges to Depakote?
Generic divalproex manufacturers used the abbreviated new drug application pathway, including patent certifications where listed patents remained relevant. Paragraph IV challenges were commercially important because they allowed generic applicants to seek approval before expiration of listed patents.
The main effects were:
- Earlier litigation over delayed-release and extended-release formulations.
- Greater pressure on Abbott and AbbVie to defend formulation claims rather than the underlying active ingredient.
- Increased probability of multiple generic approvals after the first challenge.
- Reduced value of later patent assertions once substitutable generic formulations reached pharmacies.
The practical result was generic entry across several dosage forms. Depakote did not retain a patent position comparable to a product with a current composition-of-matter patent or a durable biologic exclusivity period.
What patent litigation affected Depakote?
Depakote litigation had two separate dimensions: generic entry disputes and government enforcement involving off-label promotion.
Generic and formulation litigation
The commercial disputes concerned whether generic products infringed formulation or release patents and whether listed patents were valid. Those disputes were more consequential for timing than for long-term market structure. Once multiple generic products obtained approval, litigation could delay individual entrants but could not restore branded pricing power.
Off-label marketing and False Claims Act enforcement
In 2012, Abbott Laboratories agreed to pay approximately $1.5 billion to resolve criminal and civil allegations concerning off-label promotion of Depakote. The government alleged that Abbott promoted Depakote for uses including dementia agitation, schizophrenia, and certain autism-related behaviors without FDA approval.[3]
The settlement included criminal and civil components and imposed a corporate integrity agreement. It affected the product’s financial trajectory in three ways:
- It imposed a large one-time cash cost.
- It increased compliance and promotional restrictions.
- It weakened the commercial value of aggressive indication expansion.
The settlement did not create new patent protection or extend Depakote’s FDA exclusivity.
How did Depakote revenue change over time?
Depakote’s revenue trajectory followed the standard pattern for a mature small-molecule product: rapid growth before broad generic entry, followed by decline as generic substitution expanded.
| Period |
Commercial condition |
Revenue direction |
| Late 1990s to mid-2000s |
Branded growth across epilepsy, bipolar disorder, and migraine prevention |
Rising |
| 2008-2011 |
Generic pressure and patent disputes |
Declining |
| 2012-2013 |
Mature generic erosion and government settlement |
Declining sharply |
| Post-2013 |
Generic-dominated market; brand sales no longer separately emphasized |
Low and declining relative to peak |
Abbott annual reports disclosed Depakote sales at approximately billion-dollar levels before and around the first major generic erosion period. Reported annual sales were roughly in the range of $1.0 billion to $1.3 billion during the late 2000s and early 2010s, depending on the reporting year and product grouping.[4]
After Abbott separated its research-based pharmaceutical business into AbbVie in 2013, Depakote was no longer a central disclosed growth product. AbbVie’s reporting emphasized newer products such as Humira, while mature products like Depakote received limited standalone financial disclosure.[5]
What is Depakote’s current revenue exposure?
Current standalone Depakote revenue is not consistently disclosed by AbbVie in public filings. The financial exposure is therefore best assessed through market structure rather than reported brand sales:
- The branded product has limited pricing leverage.
- Generic divalproex captures most U.S. prescription volume.
- Depakote contributes little to AbbVie’s current growth narrative.
- The principal economic value lies in residual brand prescriptions, institutional familiarity, and dosage-form differentiation.
- Regulatory and safety liabilities remain more relevant than patent-driven upside.
The historical peak demonstrates the size of the opportunity that generic erosion removed. It does not indicate current brand revenue.
What is the competitive landscape for divalproex?
Depakote competes against both generic valproate products and alternative therapies. Competition varies by indication.
| Indication |
Depakote or generic valproate competitors |
| Epilepsy |
Lamotrigine, levetiracetam, carbamazepine, topiramate, oxcarbazepine, phenytoin |
| Bipolar mania |
Lithium, atypical antipsychotics, carbamazepine, other mood stabilizers |
| Migraine prevention |
Topiramate, beta blockers, CGRP-targeted therapies, botulinum toxin for chronic migraine |
| Pediatric seizure treatment |
Levetiracetam, lamotrigine, ketogenic diet, other antiseizure medicines |
Generic divalproex competes primarily on price, supply reliability, dosage strength, and release profile. Depakote’s remaining differentiation is strongest where physicians or patients prefer a branded extended-release or sprinkle presentation. That differentiation is limited because FDA-approved generic alternatives cover major dosage forms.
How strong is the Depakote patent estate?
The estate is weak as a current exclusivity asset and moderate as a historical formulation estate.
Strengths
- Multiple dosage forms created earlier opportunities for formulation protection.
- Extended-release delivery supported once-daily dosing.
- The product had broad clinical adoption before generic entry.
- Regulatory familiarity reduced the need for new clinical development.
Weaknesses
- Core small-molecule exclusivity has expired.
- Generic substitution is established.
- Safety warnings restrict certain patient populations.
- No biologic exclusivity or biosimilar barrier exists.
- Formulation patents cannot prevent all generic divalproex products.
- Mature generic pricing limits the value of incremental brand differentiation.
Depakote is therefore not an attractive patent-extension platform unless a new delivery technology, combination product, or clinically superior formulation receives independent regulatory protection.
What formulation and manufacturing barriers remain?
Manufacturing barriers are operational rather than legally exclusionary. Divalproex products require control of:
- Enteric coating performance for delayed-release products.
- Extended-release dissolution profiles.
- Content uniformity across strengths.
- Particle or granulation characteristics.
- Stability and impurity control.
- Bioequivalence across release technologies.
These requirements can delay individual generic applicants or cause supply disruptions, but they do not create durable market exclusivity. Contract manufacturers and established generic companies generally have the technical capacity to reproduce the relevant dosage forms.
The most defensible commercial niche would involve a differentiated delivery system, improved tolerability, pediatric administration, or a combination product. A new product would still face clinical, regulatory, and reimbursement hurdles.
Are biosimilar risks relevant to Depakote?
No. Depakote is a chemically synthesized small molecule. It is subject to the abbreviated new drug application pathway for generics, not the biologics license application and biosimilar pathway.
The relevant risks are:
- Additional generic approvals.
- Price compression.
- Authorized generic competition.
- Payer-mandated substitution.
- Supply concentration among a small number of manufacturers.
- Product-liability and reproductive-safety exposure.
Which companies are challenging Depakote commercially?
The market is challenged by generic manufacturers rather than by a single branded competitor. FDA-approved generic divalproex products have been marketed by multiple companies over time, including large U.S. and international generic manufacturers.
The competitive threat is fragmented. No single generic company needs to displace Depakote across all indications. Pharmacy benefit managers and wholesalers can shift volume among approved suppliers based on price, availability, and contract terms.
Alternative branded therapies are more important in new treatment decisions than in legacy Depakote prescriptions. In epilepsy and bipolar disorder, physicians may select newer agents based on tolerability, interaction profiles, reproductive safety, and guideline preferences.
What generic launch scenarios exist for Depakote?
Base case
Generic divalproex remains the dominant product, with stable clinical demand but continued low pricing. Depakote retains a small branded segment in selected patients and dosage forms.
Downside case for the brand
Further payer restrictions, additional generic suppliers, or a safety-driven prescribing shift reduce branded volume. The brand becomes commercially immaterial outside limited physician or patient preference segments.
Upside case for a reformulated product
A new formulation improves adherence, reduces gastrointestinal effects, or addresses pediatric administration. The opportunity would depend on new FDA approval and separate patent protection. It would not arise from the legacy Depakote estate alone.
What licensing deals involve Depakote?
No major current licensing transaction is central to Depakote’s market outlook. The product was developed and commercialized within Abbott’s pharmaceutical business and later transferred into AbbVie’s portfolio structure. The absence of a material current licensing platform reflects the product’s mature, generic-dominated status.
Licensing value would be more likely to arise from:
- A new controlled-release technology.
- A pediatric delivery platform.
- A combination therapy.
- Rights in emerging markets where generic penetration is lower.
- Manufacturing or distribution arrangements.
What is the geographic market outlook?
The United States has the most mature generic substitution environment. Western Europe and other regulated markets also have extensive generic competition, although reimbursement systems and brand-prescribing practices vary.
Emerging markets may retain stronger branded demand where:
- Generic quality perceptions differ.
- Local registration is incomplete.
- Brand loyalty is stronger.
- Distribution is concentrated.
- Pricing is not fully reference-based.
Geographic expansion is unlikely to recreate Depakote’s historical U.S. revenue because valproate is an established, low-cost therapy with broad generic availability.
Key Takeaways
- Depakote is divalproex sodium, a mature small-molecule medicine used in epilepsy, bipolar mania, and migraine prevention.
- Its core U.S. patent and regulatory exclusivity have expired.
- Generic divalproex dominates the market across delayed-release and extended-release presentations.
- Historical annual sales were approximately $1.0 billion to $1.3 billion before broad generic erosion.
- AbbVie does not provide a consistently reported standalone current Depakote revenue figure.
- The product has no biosimilar exposure.
- The principal legal event was Abbott’s approximately $1.5 billion 2012 off-label marketing settlement.
- Remaining commercial value is concentrated in residual brand use, dosage-form preference, and market familiarity.
- Patent strength is weak for current exclusivity and moderate only as a historical formulation asset.
- Future value would require a separately protected reformulation or combination product.
FAQs
Does Depakote still have patent protection?
Legacy formulation and product patents have expired or no longer prevent routine generic entry. Depakote does not have a current patent position that blocks the established generic divalproex market.
Is Depakote still a blockbuster drug?
Historically, yes. It generated roughly billion-dollar annual sales before generic erosion. It is not generally treated as a current blockbuster growth asset because standalone brand revenue is limited and not consistently disclosed.
Is generic divalproex as effective as Depakote?
FDA-approved generic products must satisfy applicable quality and bioequivalence requirements for their dosage forms. Clinical substitution depends on formulation, release profile, prescriber judgment, and patient response.
What safety issue most affects Depakote’s market?
Reproductive and fetal-risk concerns are among the most commercially important restrictions. Hepatotoxicity and pancreatitis warnings also limit use in selected patients.[1]
Can a company obtain new patents on a Depakote reformulation?
Yes. A genuinely new formulation, delivery system, combination product, or manufacturing process may qualify for patent protection if it meets patentability requirements. Any new product would require separate FDA regulatory support and would compete against inexpensive generic valproate.
References
- U.S. Food and Drug Administration. (2024). Depakote (divalproex sodium) prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Department of Justice. (2012). Abbott Laboratories agrees to pay $1.5 billion to resolve criminal and civil investigations of off-label promotion of Depakote.
- Abbott Laboratories. (2008-2012). Annual reports and Form 10-K filings.
- AbbVie Inc. (2013-2023). Annual reports and Form 10-K filings.
